Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
Enanta Pharmaceuticals, Inc. (ENTA)
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.enanta.com/investor-overview
Company Research
Source: Business Wire
Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV Patients in 2H 2024Selection of Chronic Spontaneous Urticaria (CSU) Development Candidate Targeted for Q4 2024Operations Supported by Cash and Marketable Securities Totaling $300.3 Million at March 31, 2024, as well as Continuing Retained Royalties WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024.“At Enanta, we are committed to advancing the first antiviral treatment for RSV, and more broadly developing important medicines in virology and immunology. Our commitment is highlighted by our goal to deliver multiple RSV data readouts this year, including from our challenge study of EDP-323, an oral
Show less
Read more
Impact Snapshot
Event Time:
ENTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENTA alerts
High impacting Enanta Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ENTA
News
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Enanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $28.00 to $27.00. They now have a "buy" rating on the stock.MarketBeat
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at JMP Securities from $23.00 to $22.00. They now have a "market outperform" rating on the stock.MarketBeat
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
ENTA
Earnings
- 5/6/24 - Miss
ENTA
Sec Filings
- 5/8/24 - Form S-8
- 5/8/24 - Form 10-Q
- 5/6/24 - Form 8-K
- ENTA's page on the SEC website